6/21/2013

PTC Therapeutics secured more than $125 million in an initial public offering and plans to use the proceeds to support research and development and for working capital. The New Jersey firm's lead drug candidate ataluren is designed to treat patients with genetic disorders caused by single-point mutations.

Related Summaries